Remote Patient Monitoring

Back Bay Life Science Report

Το περιεχόμενο παρέχεται από το Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

3y ago 26:30

MP3•Αρχική οθόνη επεισοδίου

One of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. Just ahead of the pandemic, investment in patient monitoring was booming; priming the system for quick uptake and innovation. As with vaccines, much groundwork had been done to prepare for dramatic innovation and widespread, rapid patient use, seemingly “overnight.”

In this episode of Back Bay Life Science Advisors' industry podcast, Drs. Jonathan Gertler and Corinne Nawn discuss the clinical considerations of remote patient monitoring, including advances in sensing platforms, wearables, and the current investment landscape driving the innovations allowing patients and physicians to interact meaningfully and safely from different locations.

Topics in this podcast include:

Investment in digital healthcare companies
- The spectrum of financings, acquisitions, IPOs, and SPACs in this space
New ways of patient monitoring through wearable tech
Understanding the details of sensing and capturing
Coordinating care based on analytics
Company partnerships and/or acquisitions

Read about MedTech's ascendance from Jonathan Gertler here.

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

28 επεισόδια

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech